MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

Single Dose Study of PF-06815345 in Healthy Subjects

Phase 1
Terminated
Conditions
Hypercholesterolemia
Interventions
Other: Placebo
First Posted Date
2016-01-13
Last Posted Date
2018-09-28
Lead Sponsor
Pfizer
Target Recruit Count
25
Registration Number
NCT02654899
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Dextromethorphan Pediatric Acute Cough Study

Phase 4
Terminated
Conditions
Cough
Interventions
Drug: Placebo
Device: Cough recording device
First Posted Date
2016-01-08
Last Posted Date
2021-04-28
Lead Sponsor
Pfizer
Target Recruit Count
131
Registration Number
NCT02651116
Locations
🇺🇸

Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States

🇺🇸

Rapid Medical Research, Inc, Cleveland, Ohio, United States

🇺🇸

Meridian Clinical Research LLC, Omaha, Nebraska, United States

and more 13 locations

A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.

Phase 2
Completed
Conditions
Non-metastatic Breast Cancer
Interventions
First Posted Date
2016-01-08
Last Posted Date
2018-10-23
Lead Sponsor
Pfizer
Target Recruit Count
25
Registration Number
NCT02650193
Locations
🇭🇺

CRU Hungary Kft.,CRU Early Phase Unit, Miskolci Semmelweis Kórház és Egyetemi Oktató Kórház, Miskolc, BAZ Megye, Hungary

🇭🇺

Debreceni Egyetem Klinikai Központ, ÁOK, Onkológiai Klinika, Debrecen, Hajdú-bihar Megye, Hungary

🇭🇺

Országos Onkológiai Intézet, Budapest, Hungary

and more 4 locations

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Phase 1
Completed
Conditions
Neutropenia
Interventions
First Posted Date
2015-12-14
Last Posted Date
2016-07-15
Lead Sponsor
Pfizer
Target Recruit Count
153
Registration Number
NCT02629289
Locations
🇦🇺

CMAX (a Division of IDT Australia Limited), Adelaide, South Australia, Australia

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Phase 1
Terminated
Conditions
Prostatic Neoplasms
Interventions
Biological: PF-06755992
Biological: PF-06755990
Device: TDS-IM Electroporation Device
Biological: Tremelimumab
Biological: PF-06801591
Biological: PF-06753512
First Posted Date
2015-11-26
Last Posted Date
2023-11-02
Lead Sponsor
Pfizer
Target Recruit Count
91
Registration Number
NCT02616185
Locations
🇺🇸

Banner-University Medical Center Tucson, Tucson, Arizona, United States

🇺🇸

The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

🇺🇸

Garden State Urology, Whippany, New Jersey, United States

and more 14 locations

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-11-20
Last Posted Date
2016-05-09
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT02609139
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Phase 3
Completed
Conditions
Bone Metastasis
Cancer Pain
Interventions
First Posted Date
2015-11-20
Last Posted Date
2023-02-16
Lead Sponsor
Pfizer
Target Recruit Count
156
Registration Number
NCT02609828
Locations
🇦🇷

Instituto de Oncologia de Rosario, Rosario, Santa FE, Argentina

🇦🇺

Monash Medical Centre, East Bentleigh, Victoria, Australia

🇦🇹

Nuhr Medical Center, Senftenberg, Austria

and more 84 locations

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

Completed
Conditions
Rheumatoid Diseases
Ankylosing Spondylitis
Rheumatoid Arthritis
Psoriatic Arthritis
Interventions
First Posted Date
2015-11-16
Last Posted Date
2020-01-13
Lead Sponsor
Pfizer
Target Recruit Count
351
Registration Number
NCT02605642
Locations
🇨🇦

The Waterside Clinic, Barrie, Ontario, Canada

🇨🇦

Adachi Medicine Professional Corporation, Hamilton, Ontario, Canada

🇧🇬

Diagnostic Consultative Center 17 Sofia EOOD, Sofia, Bulgaria

and more 35 locations

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

Phase 3
Completed
Conditions
Urothelial Cancer
Interventions
Biological: Avelumab
Other: Best Supportive Care
First Posted Date
2015-11-11
Last Posted Date
2024-03-27
Lead Sponsor
Pfizer
Target Recruit Count
700
Registration Number
NCT02603432
Locations
🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

🇳🇴

Bildediagnostisk avdeling, Nordbyhagen, Norway

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 357 locations

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

Phase 1
Terminated
Conditions
Hodgkins Lymphoma
Interventions
First Posted Date
2015-11-11
Last Posted Date
2020-04-24
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT02603419
Locations
🇮🇹

Az. Ospedaliera-Univers. di Bologna Policlinico S.Orsola-Malpighi, Bologna, BO, Italy

🇺🇸

City of Hope, Duarte, California, United States

🇮🇹

Istituto Clinico Humanitas U.O. Oncologia ed Ematologia, Rozzano, Milano, Italy

and more 9 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy